Investigation of the effect of empagliflozin on cardiac sympathetic and parasympathetic nerve activity in Japanese patients with type 2 diabetes

Authors [No authors listed]
Category Primary study
Registry of TrialsUMIN Clinical Trials Registry
Year 2017
Links ICTRP
INTERVENTION: Empagliflozin 10mg qD will be administrated in group EMPA. Empagliflozin could be used upto 25mg qD during 12‐24 weeks after the administration. Sitagliptin 50mg qD will be administrated in group SITA. Sitagliptin could be used upto 100mg qD during 12‐24 weeks after the administration. CONDITION: Diabetes Mellitus (type 2) PRIMARY OUTCOME: Changes from the baseline in LF, HF, and LF/HF ratio at the 24 weeks after the treatment. LF and HF will be estimated by heart rate valiability from 24‐hour Holer ECG dataset,; calcurated by spectral analysis. INCLUSION CRITERIA: 1) DM Patients with 7.0%
Epistemonikos ID: 72b4e44dfb40929ae6415d7f5a797548b13ea869
First added on: Aug 23, 2024